|Bid||0.0000 x 800|
|Ask||0.0000 x 2200|
|Day's Range||2.1100 - 2.2700|
|52 Week Range||1.7900 - 13.5200|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 11, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.40|
NEW YORK, May 13, 2022--PAVmed and Lucid Diagnostics Chairman & CEO Lishan Aklog, M.D. named Top 50 Healthcare Technology CEO.
NEW YORK, May 11, 2022--Lucid Diagnostics provides business update and preliminary first quarter 2022 financial results.
NEW YORK, May 09, 2022--Lucid’s first commercial payer agreement provides in-network access and payment for its EsoGuard® DNA test to over 8 million covered lives.